Target type: biologicalprocess
Any process that increases the rate, frequency, or extent of the controlled release of molecules that form the extracellular matrix, including carbohydrates and glycoproteins by a cell or a group of cells. [GOC:dph, GOC:tb]
Positive regulation of extracellular matrix constituent secretion is a fundamental biological process that governs the controlled release of proteins and other molecules that form the extracellular matrix (ECM). The ECM is a complex network of molecules that surrounds cells, providing structural support, regulating cell behavior, and influencing tissue development and function.
This process is intricately regulated by a cascade of signaling events involving various cellular components, including:
* **Transcription Factors:** Specific transcription factors, such as Smad proteins, activate genes responsible for the production of ECM constituents.
* **Signaling Pathways:** Growth factors like TGF-beta and FGF, along with signaling pathways such as the MAPK and Wnt pathways, initiate intracellular signaling cascades that modulate gene expression and ECM secretion.
* **Cytoskeleton:** The cytoskeleton, a network of protein filaments within the cell, facilitates the transport and secretion of ECM molecules.
* **Secretory Vesicles:** ECM constituents are packaged into secretory vesicles, which then move towards the cell membrane for release.
* **Exocytosis:** The fusion of secretory vesicles with the cell membrane releases ECM components into the extracellular space.
The process of positive regulation of ECM constituent secretion involves a series of interconnected steps:
1. **Signal Reception:** Cells receive signals from their environment, including growth factors, hormones, and mechanical cues.
2. **Signal Transduction:** These signals are relayed through intracellular signaling pathways, activating specific transcription factors.
3. **Gene Expression:** Activated transcription factors bind to regulatory regions of genes encoding ECM proteins, leading to increased transcription.
4. **Protein Synthesis and Modification:** The transcribed genes are translated into proteins, which undergo modifications and folding processes.
5. **Packaging and Transport:** ECM proteins are packaged into secretory vesicles and transported towards the cell membrane.
6. **Exocytosis and Release:** Secretory vesicles fuse with the cell membrane, releasing the ECM components into the extracellular space.
**Regulation of ECM Secretion:**
* **Positive Feedback Loops:** The ECM itself can influence its own secretion, creating positive feedback loops.
* **Negative Regulation:** Cells have mechanisms to control and restrict ECM production to maintain tissue homeostasis.
* **Disease Processes:** Dysregulation of ECM secretion is implicated in various diseases, including fibrosis, cancer, and inflammation.
In summary, positive regulation of extracellular matrix constituent secretion is a precisely regulated process that involves multiple cellular components and signaling pathways. It is essential for maintaining tissue integrity, regulating cell behavior, and supporting tissue development and repair. Understanding this process is crucial for addressing various pathological conditions associated with ECM dysfunction.'
"
Protein | Definition | Taxonomy |
---|---|---|
Carboxypeptidase B2 | A carboxypeptidase B2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q96IY4] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
benzylsuccinic acid | 2-benzylsuccinic acid : A dicarboxylic acid consisting of succinic acid carrying a 2-benzyl substituent. benzylsuccinic acid: inhibitor of carboxypeptidase A | dicarboxylic acid | bacterial xenobiotic metabolite |
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2. | aromatic ether; C-nitro compound; sulfonamide | antineoplastic agent; cyclooxygenase 2 inhibitor |
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
sq 24798 | 2-mercaptomethyl-5-guanidinopentanoic acid: structure | ||
anabaenopeptin b | anabaenopeptin B: from cyanobacteria Planktothrix (Oscillatoria) rubescens |